Skip to main content

1 Result(s)

within Shengqiang Huang Remove this filter Hematology Remove this filter

and

  1. No Access

    Article

    An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin’s lymphoma

    Anti-PD-1 immunotherapy has been widely applied in patients with some types of lymphoma. Classical Hodgkin’s lymphoma (cHL) is highly sensitive to immunotherapy, but non-Hodgkin’s lymphoma (NHL) does not show ...

    Lin Yang, Qiuling Zhao, Ting Chen, Wenbin Liu… in Clinical and Experimental Medicine (2023)